Background: The European Organization for Research and Treatment of Cancer (EORTC) QLQ-LC13 was the first module to be used in conjunction with the core questionnaire, the QLQ-C30. Since the publication of the LC13 in 1994, major advances have occurred in the treatment of lung cancer. Given this, an update of the EORTC QLQ-LC13 was undertaken.
Introduction
Lung cancer is the most common cancer worldwide, accounting for 1.2 million new cases annually, as well as the most lethal solid malignancy [1, 2] . According to a recent review by Islami et al. [3] , lung cancer is the leading cause of cancer death in men in 87 countries and in women in 26 countries, with the latter largely confined to high-income countries [4] . Smoking is the most common cause of lung cancer constituting 85% of cases, followed by work-related pollutants (8%), and air pollution (5%) [5] [6] [7] .
These facts highlight the importance of pushing lung cancer research forward. Recognizing the growing importance of quality of life (QoL) as an end point in clinical studies, the European Organization for Research and Treatment of Cancer (EORTC) has developed a questionnaire module for the assessment of QoL in lung cancer patients to be used in conjunction with the core questionnaire QLQ-C30 [8] . As its name suggests, the QLQ-LC13 consists of 13 items. The module has been translated into >60 languages and is considered one of the standard instruments for measuring QoL in patients with lung cancer [9, 10] .
Since its publication in 1994, major advances have been made with regard to diagnostic and therapeutic options. New advanced imaging techniques such as positron emission tomography-computed tomography (PET-CT) [11] and endobronchial ultrasound [12] allow refined lung cancer staging and can thus prevent futile thoracotomies. New medical therapies such as targeted agents [13, 14] prolong survival but may involve side-effects other than those traditionally known with chemotherapy. Modern radiotherapy techniques such as the integration of fourdimensional CT for planning intensity-modulated radiotherapy have improved the accuracy of irradiation delivery [15] [16] [17] . Surgery remains the best curative option in early-stage disease and is part of a multimodality approach for patients with resectable, locally advanced tumors [18, 19] .
In order to keep pace with recent developments and cover newly emerging QoL issues and toxicity, the EORTC QoL group (QLG) decided to update the LC13.
Method Overview
The EORTC QLG has implemented a four-phase methodology to develop modules [20] , and phases I to III are described in the current article. Approval was obtained from the Ethics Committee of the University of Regensburg (31 March 2011, reference number 11-101-0024). In addition, the study protocol was approved by local ethical committees according to the national requirements. The study was registered with clinicaltrials.gov (ClinicalTrials.gov, Identifier: NCT01434784).
Phase I
During phase I, a comprehensive list of QoL issues relevant to lung cancer patients was generated, using different sources of information. First, an extensive systematic literature search was carried out that covered clinical studies with the LC13 as an outcome measure [21] . Second, a total of 29 questionnaires on lung cancer and respiratory illnesses were analyzed [22] [23] [24] [25] . Third, investigator brochures of new medications tested in international clinical trials on lung cancer patients were scrutinized for adverse and serious adverse events. Fourth, nine health care professionals at the University Hospital Regensburg representing different disciplines (pneumology, thoracic surgery, oncology, radiotherapy, nursing, and clinical psychology) were invited to a 2-hour nominal group process [26] to generate issues that were important with regard to the therapy, symptoms, and experiences of lung cancer patients. Fifth, patients and health care providers responded to a comprehensive list of issues and rated their relevance and priority to be included in a QoL questionnaire for lung cancer patients.
Phase II
Issues that were identified as relevant in phase I were transformed into questionnaire items according to the EORTC QLQ format. In order to ensure uniform wording across different EORTC modules, items were recycled from the item bank [27] whenever possible.
Phase III
Procedure. The provisional updated lung cancer module was pretested in a phase III study with the goal to assess the relevance and acceptance of the items and to find out whether any important issues were missing. Patients first filled in the QLQ-C30 and the updated provisional lung cancer module that comprised 48 items. Then patients were interviewed about their opinion regarding the updated module. Using a yes/no answering format, patients were asked whether they found each of the 48 items either relevant (¼should be included in the questionnaire), confusing (¼difficult to understand), or annoying. Finally, patients answered open-ended questions asking whether any items should be omitted or whether any issues were missing or should be reformulated.
Patient inclusion criteria were as follows: histologically confirmed diagnosis of either non-small-cell lung cancer (NSCLC) or small-cell lung cancer, no previous other primary or recurrent tumor, mentally fit to complete a questionnaire, able to understand the language of the questionnaire, 18 years of age or above (no upper age limit), and written informed consent. Patients who did not meet all these inclusion criteria were excluded.
Since the histological type of disease and the disease stage determine the choice of treatment and treatment in turn is mainly responsible for changes in QoL (to the worse or better), main stratification criteria were the type of therapy and the timing of treatment. The sample matrix specifies three main groups of the primary therapy: surgery, radiochemotherapy, or targeted therapy. The singular use or combination of these therapies yielded nine subgroups ( Table 1 ). The time frames of QoL assessment were chosen so that symptoms and side-effects were likely to be present and detectable by means of the questionnaire.
Decision criteria for selecting items. In line with recommendations of the EORTC Module Development Guidelines [20] , the following quantitative decision criteria and cut-off points were defined a priori:
• item rated relevant by > 80% of the patients;
• item rated difficult to understand by < 5%; • item rated annoying or intrusive by < 5%;
• mean score >1.5;
• prevalence of item scores 3 or 4 in > 30%;
• no floor effect (floor effect exists if > 90% check 1 or 2); • no ceiling effect (ceiling effect exists if > 90% check 3 or 4);
• range >2 score points on the 1-4 scale;
• no missing responses (<10%).
Patients scored 1 point for each of the nine criteria that they fulfilled. An item was considered eligible for inclusion if six of the nine criteria were met. In addition to these quantitative criteria, we also considered qualitative statements by patients in the open interview and judgments by experts of the study group.
Statistical analyses. Data from patient and health care provider interviews and questionnaires were analyzed using basic descriptive statistics: counts, percentages, means and SDs, medians, and ranges. Patient ratings regarding relevance, comprehensiveness, and intrusiveness of the items were calculated for the entire sample of patients as well as for the therapeutic subgroups surgery, chemotherapy, radiotherapy, radiochemotherapy, and targeted therapy.
In addition, we carried out preliminary psychometric analyses (Cronbach's a) to explore a hypothesized scale structure. IBM SPSS Statistics 23.0 (IBM Corporation, Armonk, NY) was used as the statistical analysis tool.
Results
Phase I: Analyzing patients' and health care providers' responses to the list of potentially relevant QoL issues
The literature searches and the focus group resulted in a list of 110 potentially relevant QoL issues that in a next step were rated by patients and health care providers from 7 countries (Austria, Germany, Italy, Norway, Spain, Taiwan, and the UK).
A total of n ¼ 108 patients, all with histologically confirmed diagnosis of lung cancer, were enrolled. Sixty percent of the patients were male, patients' median age was 64 years (range, 32-88; mean ¼ 64.01, SD ¼ 10.87), 81% had NSCLC, 53% were treated with multimodal therapy, and the median Karnofsky performance status was 90 (range, 50-100; mean ¼ 83.49, SD ¼ 12.76).
A total of n ¼ 103 health care providers, 51% females, representing >5 different disciplines (pneumology, thoracic surgery, oncology, nursing, and other) with a solid level of professional experience (59% being >5 years in their profession) participated.
An a priori defined set of threshold criteria were applied, and the empirical results were discussed within the study group. As a result, 53 issues were retained (Table 2) .
Phase II
On the basis of the issue list, a provisional module was created. As a first step, the EORTC item bank was searched for appropriate items [27] . Following the advice of the EORTC Translation Unit, four of the original QLQ-LC13 items (Nos. 31, 33, 34, and 35) were slightly rephrased ('Have you been short of . . .' instead of 'Were you short of . . .') in order to enhance their translatability. Table 2 . Quality-of-life issues as rated by patients and health care professionals in phase I
The following 53 issues were evaluated relevant: Acne, allergic reactions, amnesia, anorexia, conjunctivitis, coughing up blood, decrease in performance, delusional memories, discomfort because of nicotine dependence, discomfort of treatment, disturbances in swallowing, dizziness, dry cough, dryness of mouth, eating disorder, economic anxieties, effect of the cancer on a patient's social life, existential fear, eye pain, eyelash growth, fear of dyspnea/shortness of breath, fear of immobility, fear of lack of efficacy of therapy, fear of oxygen dependence, fear of pain, fear of suffocation, fear of the future and of death, fear of tumor progression, fear of wound pain, feeling exhausted, feeling of sickness/nausea, hair change, hair loss, inflammation of mucosa, invalidity, lethargy, loss of control, mortal fear, nail changes, oxygen dependence, paresthesia, performance restrictions due to extent of surgery, sensibility disorders in the area of surgery, sexual dysfunctions, shoulder pain, skin changes, smoking (yes/no), social withdrawal, stigmatization ('to be doomed to die'), sudden change of life because of the illness, uncertainty, weakness, weight loss, wound pain in the area of surgery The following 57 issues were not rated relevant: Abdominal pain, body image, bone fractures, cardiac arrhythmia, cardiac insufficiency, changes in blood count, claustrophobia, complications, cosmetics, dry eyes, duration of treatment, family planning, fear of additional therapies, fear of anesthesia, fear of hospitalization, fear of radiation therapy, feeling regret, feelings of regret and self-blame, fertility disorders, fever, foreign body sensation, fractured rib, hemorrhagic complications, handling of drainages, heteronomy, hypertension, injury tendency, kidney function disorders, lack of consciousness, loss of hearing, menstrual disorders, mucosal reactions, muscular atrophy, neurological deficiencies, night sweat, nosebleed, occupation, panic attacks, polyneuropathia, postoperative symptomatic transitory psychotic syndrome, professional exit, proteinuria, rash (itching), reservations about chemotherapy, reservations about radiotherapy, resumption of professional activities, return to work, smell disorder, smoking (feelings of self-blame/regret for having smoked in the past), subjection to technology, susceptibility to infections, tachycardia, taste disorder, unawareness/lack of knowledge, uncertainty of diagnosis, visual disorders, wound healing disorder.
Note. Issues were considered relevant when they received relevance ratings of ! 2 by patients or of ! 3 by health care providers (on a 1¼ not relevant to 4 very relevant scale) and/or priority ratings (i.e. should be included in questionnaire) of ! 30% of the respondents. The provisional module also included an ad hoc scale on symptoms of patients who had undergone lung cancer surgery. This scale had been developed and published outside the EORTC and had never been formally psychometrically validated [28] . Nevertheless, in terms of content, the items appeared useful for surgical patients, and the lead author granted permission to use the scale. In addition, three surgery-specific items were developed by our own group and were put in front of the ad-hoc scale: 'Have you had pain in the area of surgery?'; 'Has the area of your wound been oversensitive?'; 'Were you restricted in your performance due to the extent of surgery?' (items 55-57, see Appendix).
In summary, the provisional module consisted of 48 items. The number of items is slightly lower than the number of issues because of the redundancy of some issues (e.g., 'discomfort of treatment' not used as a separate question but represented by numerous side-effect symptoms).
Phase III Patient characteristics. Two hundred patients participated in this international multicenter study (Table 3) . Patients were recruited in 12 centers from nine countries, representing Northern (Germany, Norway; n ¼ 80 patients), Southern (Cyprus, Israel, Italy, Spain; n ¼ 60), Eastern (Poland; n ¼ 30), English-speaking (UK; n ¼ 28), and non-European (Taiwan; n ¼ 2) regions.
Median age was 65 years (range, 39-91; mean ¼ 63.76, SD ¼9.04), and there were more men (59%) than women ( Table  2) . Most patients had advanced disease (NSCLC IV, 38.5%), suffered from various comorbidities (66.5%), and were treated with palliative intent (56%). Patients were divided into three main treatment groups according to the primary therapy: surgery (n ¼ 58), radiochemotherapy (n ¼ 113), and targeted therapy (n ¼ 29). Quantitative and qualitative item analyses. As can be seen in Table 4 , 27 items met the quantitative decision criterion of six points. Patients (41/200; 20.5%) responded to the open-ended question that asked whether anything should be deleted. Most comments referred to the bundles of questions related either to cough, dyspnea, pain, and existential issues. In all instances, patients suggested to minimize the number of items. More specifically, the number of patients suggesting reductions in the respective areas were n ¼ 19 (dyspnea), n ¼ 15 (pain), n ¼ 13 (existential issues), and n ¼ 5 (cough). Patients (n ¼ 11) suggested to delete the item on sexuality (item 54) because it was either too intimate or not applicable ('live alone').
Patients (68/200; 34%) responded to the open-ended question that asked whether any issues were missing. More than three patients missed aspects of religion and spirituality, positive aspects of life, family issues and satisfaction with care, and the patient-physician relationship. Other issues that were eventually mentioned were remorse of ever having smoked as well as radiotherapeutic and esophageal symptoms.
Summary of the findings on item selection. Twenty-seven items met the quantitative decision criterion of six points. Two additional items that scored 5 in the overall sample received more favorable ratings in subgroup analyses (radiotherapy and targeted therapy) and were thus included (Table 4) . Surgery-specific items Have you had pain in the area of surgery? 55 9 Has the area of your wound been oversensitive? 56 9 Were you restricted in your performance due to the extent of surgery? 57 9 Have you had any difficulty using your arm or shoulder on the side of the chest operation? 58 9 Has your scar pain interfered with your daily activities? 59 8 a Decision criteria included patients' ratings of relevance, difficulty to understand, and intrusiveness, as well as distribution characteristics such as mean score, prevalence of item scores, floor effect, ceiling effect, range, and missing responses. The decision score had a range from 0 to 9 (maximum), and 6 was considered the threshold. A total of 19 items were excluded. Eleven items were eliminated because they were redundant, five items failed the quantitative criteria, one item was difficult to understand, and one item had too many missing responses. One item was not considered because it referred to overall satisfaction with surgery using a sevenstep response scale.
In summary, most decisions to exclude items were guided by the principle to avoid redundancies and keep the length of the module acceptable. The final updated phase III module contains a total of 29 items, 24 general and 5 surgery specific.
Hypothesized scale structure. Based on the item content (face validity) and the preliminary psychometric analyses, the following hypothesized scale structure is proposed (Table 5) : five multiitem scales (coughing, shortness of breath, side-effects, existential issues related to tumor progression, and surgery-related symptoms) and five single items (coughing up blood, pain in chest, arm/shoulder and other parts of the body, and weight loss). Cronbach's a's for the five multi-item scales exceed the commonly accepted threshold of 0.70 [29] . It is noteworthy that the three single items on pain did not add up to a consistent scale, with Cronbach's a as low as 0.52.
Discussion
From phases I and II of the EORTC's standardized module development approach, it became clear that the LC13 should be supplemented with new items to assess the effects and side-effects of the various therapeutic options that are currently available to lung cancer patients. These preparatory phases resulted in a provisional 48-item module. The goal of the international, cross-cultural, multicenter phase III study was to test this provisional module regarding relevance, acceptability, comprehensibility, and completeness.
An important result of this phase III study was that 12 out of the 13 original LC13 items could be retained in the updated version: items 31 to 42 were taken from the original questionnaire, items 43 to 59 were newly added (see Appendix). This allows some comparability of data from studies that either employed the original or the updated module.
The 12 original items are accompanied by 17 new items, which suggests calling the updated module EORTC QLQ-LC29. The updated module contains 12 items that cover potential sideeffects of medical and targeted therapies, such as splitting fingernails or burning eyes. Two new items address existential issues. Such issues may appear intrusive or insensitive, but received high relevance ratings by our patients. Thus, the items may help detect psychosocial add-on effects of new therapies as well as identify the need for supportive care and social support [30, 31] .
The updated module contains a five-item subscale specifically designed to address issues of patients who had undergone surgery for lung cancer (e.g. pain, restriction in performance). We used a published scale as a starting point [28] and supplemented it with three items developed by our own group. The published scale was developed outside the EORTC and had never been psychometrically tested. Based on the results of our phase III study, only two out of the original nine items were retained, but their wording had to be changed to be consistent with EORTC standards.
Our five-item subscale enables thoracic surgeons to assess the outcome of surgical management. Should its psychometric properties be confirmed in the phase IV study, this will provide surgeons with the first fully validated thoracic surgical QoL assessment tool for patients with lung cancer [32] . The idea is to use this subscale as an option in studies that involve multimodal therapies with a surgical component. In studies that focus on investigating systemic therapies, the surgical subscale may be left out.
It is also noteworthy that the updated module ends with three open-ended questions, which patients can answer if they wish to report symptoms or problems that are not covered by the questionnaire. Such an open-format option is useful in an era of rapidly emerging medical options and also provides an empirical basis for further refining the measure.
Among the currently available measures for lung cancer [33, 34] , the LC29 stands out as the questionnaire that has been developed according to a rigorous state-of-the methodology in a cross-cultural setting [20] , reflecting the QoL issues that emerge with the variety of accessible treatments. It also has to be pointed out that patients were an integral part in the updating process. A total of 308 patients participated in phases I and III to shape the scope of the new the module. Giving patients a strong voice, the EORTC fulfills an important methodological criterion of questionnaire development demanded by regulatory bodies [35] .
An international, cross-cultural, multicenter phase IV study is currently underway to fully validate the psychometric properties of the LC29. The updated lung cancer module (see Appendix) is already available for use and can be obtained in nine languages via the EORTC Quality of Life Department (groups.eortc.be/qol). 
